

EARLY BIRD REGISTRATION
SAVINGS UP TO \$300
REGISTER BY
JULY 16

CHI's 12th
International Leaders in

BIObanking

Congress **Virtual**

October 12, 2021

ONE DAY EVENT

🕒 [EDT]

2021
SPEAKERS
INCLUDE:

Innovations to Maintain Integrity and Maximize
Investment in Biospecimens



Nahla Afifi
Qatar Biobank



James Beck
Parkinson's
Foundation



**Marta
Castelhana**
Cornell Veterinary
Biobank



**Dianne
Chadwick**
Sunnybrook



Zuanel Diaz
Miami Cancer
Institute



Tatiana Foroud
Indiana University
School of Medicine



Tom McDonald
Bristol-Myers
Squibb



**Melissa
Rawley-Payne**
Lupus Research
Alliance




**Catherine
Sainsbury**
Intermountain
Health



**Michael
Sheldon**
Infinity Biologics



Jay Tischfield
Rutgers University



Kerry Wiles
Vanderbilt
University

BiobankingCongress.com

**Dedicate 1 Day to connect virtually
with your peers during the
Leaders in Biobanking Congress 2021**

Cambridge Healthtech Institute's 12th International **Leaders in Biobanking Congress** addresses innovations in biospecimen science and infrastructure to support expanding applications. Maintaining the integrity of biospecimens allows biomedical and biopharmaceutical researchers, regulators, biorepository managers, and practitioners to investigate the best strategies for effective use of biospecimens within today's cutting-edge biomedical research. Today, flexibility and functionality are key.

TUESDAY, OCTOBER 12

**BIOBANKING MANAGEMENT: MAXIMIZING
INVESTMENT**

9:00 am Organizer's Welcome Remarks

Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute

9:05 Chairperson's Opening Remarks

Brenda Yanak, Vice President, Global Biospecimen & Imaging Management, Bristol-Myers Squibb Co.

9:10 Making a Deposit and Getting a Return – Returning Value to Participants in the PD GENERation Study

James Beck, PhD, Senior Vice President & CSO, Parkinson's Foundation

Genetic testing for Parkinson's disease is not routinely offered, but there is great scientific interest to bank DNA of people living with Parkinson's to identify new causative genes. Returning results to participants can not only meet scientific goals of sponsors but can also bring value to participants through the knowledge of their genetic status. This may have personal and clinical utility, including the potential to enroll in gene-targeted clinical trials.

9:40 Clinical Surplus from COVID Patients – The Diagnostic Bonanza

Dianne Chadwick, PhD, Biobank Coordinator, Sunnybrook Health Sciences Centre, Adjunct Lecturer and Associate Graduate Faculty, University of Toronto

Over the past year, there have been tremendous advances in our understanding of COVID-19, and protective vaccines have been developed. Laboratory Medicine will continue to play a central

role in the diagnosis and management of the disease. We will present our strategy to biobank clinical surplus blood derivatives and their use supporting research initiatives such as evaluation of the immune response to infection and vaccination in our most vulnerable populations.

10:10 Lupus Nexus: Development of a Business Plan for a Registry and Biorepository Initiative to Accelerate Lupus Research

Melissa L. Rawley-Payne, Independent Consultant, Lupus Nexus Operations Manager, Lupus Research Alliance

The Lupus Research Alliance (LRA) and its affiliate Lupus Therapeutics (LT) are committed to developing the Lupus Nexus, a registry and biorepository, as a forward-looking information exchange platform that will substantially accelerate research and clinical efforts in lupus. To plan for long-term sustainability of this initiative, the LRA/LT partnered with Deloitte to develop a formal business plan and financial model.

10:40 Communicating with Your Customers

Kerry R. Wiles, Program Director, CHTN Western Division & Tissue Repository, Pathology & Microbiology & Immunology, Vanderbilt University

The CHTN is a prospective procurement program, funded by the National Cancer Institute to procure remnant tissue from surgical and autopsy procedures for distribution for basic research and discovery. The term "prospective procurement" can be confusing to the researchers, especially if they do not understand the surgical procedures and requirements for patient diagnosis. Communication with your customers is paramount in helping them understand the complexities of the biorepositories operations.

11:10 Signature Postmortem Collection Protocol for Translational Research

Susan Garrison, Cornell University College of Veterinary Medicine

11:40 CAP Accreditation – Anatomy of Virtual Inspections and Compliance Continuity

Zuanel Diaz, PhD, Director, Biospecimen Repository & Protocol Support Lab, Baptist Health South Florida

12:10 pm Sponsored Presentation (Opportunity Available)

12:40 Lunch Break

POSTER PRESENTATIONS

1:15 Share Your Insights with the Biobanking Community with a Poster Presentation

We have set aside this time on the agenda for selected poster presentations.

- Your research will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions.
- Discuss your research and collaborate with other attendees.
- View 3-5 minute voice-over PowerPoint presentations.

For additional information please visit <https://www.biobankingcongress.com/posters>

BIOSPECIMEN SCIENCE: MAINTAINING INTEGRITY

1:30 Organizer's Welcome Back

Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute

1:35 Sample-Centric Biobanking: Andy Brooks' Legacy of Leadership

Jay A. Tischfield, PhD, Distinguished Professor, Genetics, Executive Director, Human Genetics Institute of New Jersey, Rutgers University

1:50 RUCDR to Infinity Biologix – How Technology Has Played a Role in Flexibility and Rapid Response to COVID Testing

Mike Sheldon, PhD, Senior Director, Scientific Affairs, Infinity Biologix
 RUCDR, one of the world's leading sample processing laboratories since 1998, became Infinity Biologix (IBX) in 2020. IBX then built one of the major COVID-19 testing labs in the US in response to the pandemic. A major factor was IBX's development of the first saliva-based SARS-CoV2 test to receive FDA EUA approval. We will consider the events that led to this development and the ability to perform >7.5M PCR tests.

2:20 Qatar Biobank Management Approach and Implemented Tools Used to Adapt to the COVID-19 Crises

Nahla Afifi, PhD, Director, Qatar Biobank

Qatar Biobank (QBB), similar to other biobanks all over the world, had to convert and adapt its operations to cope with this challenging period of COVID-19. This is a showcase of QBB change management highlighting QBB's Operational Resilience Plan and the implemented tools used, helping QBB to continue business as usual and providing high quality services for COVID-19 related research.

2:50 Biobanking to Support Research Discovery in Neurodegenerative Disorders

Tatiana M. Foroud, PhD, Joe C. Christian Professor Medical and Molecular Genetics, Indiana University School of Medicine

Indiana University is the home to several biorepositories focused on the support of neuroscience research, particularly in the areas of Alzheimer's Disease and related disorders and Parkinson's Disease. Key components of these efforts include uniform protocols across these disease areas to support the use of samples across studies and repositories. These national repositories are also focused on ensuring rigor and reproducibility through the use of blinded sample distributions.

3:20 Sponsored Presentation (Opportunity Available)

3:50 Session Break

4:00 Think Tank: Disaster & Recovery Plans – Facing Challenges with Flexibility

Moderator: Kerry R. Wiles, Program Director, CHTN Western Division & Tissue Repository, Pathology & Microbiology & Immunology, Vanderbilt University

Beyond the pandemic the biobanking community has also dealt with the unexpected, as well. Disaster & Recovery Plans are important strategy tools to have in place for rapid response and recovery. Learn from this seasoned group of biobank managers as they share their disaster, response, and solutions. The Think Tank will close with interactive discussions for all to share what worked, what didn't and what's next.


Panelists:

Thomas J. McDonald, MS, Associate Director, Strategic Biospecimen & Vendor Logistics Management, Bristol-Myers Squibb

Catherine Sainsbury, Manager, BioRepository & CV DNA Lab, Intermountain Healthcare

Jay A. Tischfield, PhD, Distinguished Professor, Genetics, Executive Director, Human Genetics Institute of New Jersey, Rutgers University

5:00 Close of Congress





In Memoriam

Celebrating a Leader of the Biobank Community

Andrew I. Brooks, Ph.D., 1969 - 2021 | Chief Executive Officer and Chief Scientific Officer Infinity BiologiX LLC (formerly RUCDR)

On Saturday, January 23, Andrew Ira Brooks ("Andy" to everyone) became ill suddenly and died near his Manhattan, New York home. He was 51 years of age, born and raised in New Jersey. Andy received his Ph.D. degree in Neuroscience from the University of Rochester and became their Director of Medical Center Core Facilities. Four years later he returned to New Jersey to direct the joint Rutgers/UMDNJ EOHSI Bionomics Research and Technology Center with an appointment as Research Professor in the Rutgers University Department of Genetics. In 2009 he became Chief Operating Officer and Director of Technology Development of RUCDR, Infinite Biologics®, a Rutgers public/private partnership. His career is distinguished by his scholarship, service to the field of biomedicine and business activities designed to improve human health.

[READ MORE](#)

A cluster of four hexagonal images: a hand holding a white microplate, a close-up of a microscope lens, a green 3D molecular model, and a blue abstract pattern.

**SUBMIT
A VIRTUAL
POSTER FOR
CONSIDERATION &
SAVE \$50*!**



Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the virtual poster sessions. To ensure your poster presentation is considered, your full submission must be received, and your registration paid in full by **September 17, 2021**.

Register and indicate that you would like to present a virtual poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract and other materials. **Please see [website](#) for special requirements.**

A limited number of oral poster presentation slots are available. Poster presentations will be pre-recorded oral presentations played in real-time and integrated into the conference agenda.


SPONSORSHIP & LEAD GENERATION OPPORTUNITIES

CORPORATE SPONSOR/PRESENTATION

- Thought-Leadership: 10 or 20-minute presentation
- Post-event, CHI will provide you full contact information (GDPR compliant) for entire event
- Presentation promoted in conference proceedings
- Two (2) main conference registrations
- One (1) main conference registration for your speaker
- Corporate logo in conference materials denoting Corporate Sponsorship
- Corporate logo with link within the conference proceedings denoting Corporate Sponsorship
- Additional main conference registrations available at a discount for your staff – limited to 5
- Corporate logo with link on the event website

SPONSORSHIP FEE: \$5,000 (10-minute talk)
SPONSORSHIP FEE: \$7,500 (20-minute talk)

Contact Us



For more information regarding sponsorship and exhibit opportunities, please contact:

Shannon Kresge

Business Development Manager
 +1 781-972-1343
skresge@healthtech.com

LOOKING FOR ADDITIONAL WAYS TO DRIVE LEADS TO YOUR SALES TEAM?

CHI's Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guarantee a minimum of 100 leads per program! Opportunities include:

- Live Webinars
- White Papers
- Market Surveys
- Podcasts and More

2019 ATTENDEE DEMOGRAPHICS

